M. de O. Andrade, “Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/ GBECAM-0123 study”, MAST, vol. 35, no. suppl.1, Feb. 2026.